Prabhudas Lilladher's research report on Jubilant Ingrevia
Challenging market conditions continue to persist especially for the Agrochemical sector which may take another 1-2 quarters to get back to normal. Pharmaceutical segment had healthy volumes and the Nutrition segment saw steady demand for the quarter but due to excess supply from China, realization remained under pressure. Specialty chemical saw a 30% QoQ growth primarily driven by growth in Fine chemical & Microbial and Nutrition products. The company commissioned Multi-purpose agro actives & Intermediate plant and Diketene derivatives plant in Q4FY24 and aims to invest in opportunities such as Food and Cosmetic grade Niacinamide and Multipurpose Plants. We believe that although the company is adding multiple capacities performance and margins will continue to be impacted until international players keep on dumping at lower prices.
Outlook
The stock trades at 27x FY26 EPS. Reiterate ‘Hold’ rating with SOTP based valuation of Rs526.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
